Mechanistically, treatment with entinostat was reported to increase chromatin accessibility of the IFIT1 gene promoter region, driving the epigenetic upregulation of the IFIT1-mediated IRF1, STAT4 and STING pathways, and resulting in increased NK cell cytotoxicity against tumor targets (160). Here, IFIT1 is linked to neoplasm.